Small-molecule inhibitors of the human epidermal receptor family. (Q37638679)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

review article

1 reference

title

Small-molecule inhibitors of the human epidermal receptor family (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Corey A Carter

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Ronan J Kelly

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1829-1842

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

Targeting the HER-kinase axis in cancer

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Specificity within the EGF family/ErbB receptor family signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Epidermal growth factor receptor and bladder cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

EGFR exon 20 insertion mutation in Japanese lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Activating mutations for the met tyrosine kinase receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Somatic mutations of the ERBB4 kinase domain in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

HKI-272 in non small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Biology of HER2 and its importance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903373343

10.1517/13543780903373343

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19938898%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference